Trial Profile
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Vorasidenib (Primary)
- Indications Glioma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Agios Pharmaceuticals
- 07 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 07 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.
- 16 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.